Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on April 16th, 2019 by Nicki CatchpolePharma R&D
Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.(more…)
Protected: 4P Pharma and Elsevier Life Sciences Collaborate in “the Hive” to Propel Discovery Forward
Posted on April 15th, 2019 by Nicki CatchpoleThe Hive
Posted on April 13th, 2019 by Nicki CatchpolePharma R&D
Beacon Discovery is a selected member of Elsevier’s The Hive, which is a partnership engine supporting innovation and R&D with emerging biotech startups. Here, Dr. Carleton Sage explains how leveraging the Elsevier suite of solutions in conjunction with an impassioned approach to GCPR research, Beacon Discovery has made significant strides in the discovery process to solve unmet medical needs.(more…)
Posted on April 9th, 2019 by Chris Cheadle PhDPharma R&D
Partnerships between organizations with complementary goals and capabilities are increasingly proving to pave paths towards revolutionary advancements in life sciences. One such partnership is highlighted between Elsevier and Rochester General Hospital at ConTech 2018 in the field of In Silico Disease Modelling.
Posted on April 3rd, 2019 by Saber A. AkhondiPharma R&D
Scholarly research and literature are important elements to inform the beginning stages of R&D efforts. Automated solutions that leverage capabilities such text mining enable researchers to hone in on the most relevant data and inform their research.(more…)
Posted on April 1st, 2019 by Marnix WiefferPharma R&D
It’s a well known fact that the majority of drugs in development never make it to market despite the immense amount of time, money and effort. The application of data and analytics solutions to the R&D process as early as possible has proven to be a pivotal strategy to help improve trial design.(more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.